drug
as of 2026-07-01MP-214 9mg
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Tanabe Pharma Corporation
3 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
3
Long-Term Study of MP-214 in Patients With Schizophrenia
NCT01626872Phase 2, Phase 3Completed
Safety and Efficacy of MP-214 in Patients With Schizophrenia
NCT01625000Phase 2, Phase 3Completed
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
NCT01626859Phase 2, Phase 3Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication